{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T13:11:40Z","timestamp":1768223500061,"version":"3.49.0"},"reference-count":22,"publisher":"Termedia Sp. z.o.o.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pol J Radiol"],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To count and review cases of subsequent malignant neoplasms (SMNs) in childhood cancer survivors, which are estimated to occur at a\u00a0tenfold higher frequency than in the general population<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and methods<\/jats:title>\n                    <jats:p>Data of 60 patients with SMNs from a\u00a0tertiary referral center for pediatric solid tumors were analyzed: gender, age at diagnosis, treatment, time between diagnoses, subsequent cancer\u2019s association with radiotherapy, observation time, status: alive\/dead, genetic background<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Median age at time of diagnosis of the index tumor (IT) was 6.8 years (0.1-22.1), of subsequent neoplasm 14.9 years (2.1-36.6). Median time between diagnosis of first and subsequent neoplasm was 6.3 years (0.8-26.2). In 16 patients, secondary tumors developed in irradiated sites. Eleven patients (18.3%) had cancer predisposition syndromes (CPS): 3 RB1 mutation, 5 Li-Fraumeni syndrome, 4 neurofibromatosis type 1; one had both Li-Fraumeni syndrome and RB1 mutation. Four patients (3 with CPS) had a\u00a0third malignant neoplasm, and three had a\u00a0fourth. Thirty-seven patients (61.6%) are alive, 23 (38.4%) died. Median observation time is 15.0 years (1.3-43.1). The overall 5-year survival rate in the whole group is 85% from diagnosis of IT. The overall 5-year survival rate from diagnosis of the second tumor is 63%<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Due to risk of SMNs, life-long cancer screening is required for childhood cancer survivors. In CPS, this risk is multiplied, as it results from both genetic factors and previous treatment; in these patients, multiple primary cancers must be taken into account. When assessing imaging studies of patients with a\u00a0history of malignancy, clinicians should consider not only recurrence and metastases but also the possibility of a\u00a0new malignancy of a\u00a0different histopathological nature<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5114\/pjr\/213904","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T10:02:52Z","timestamp":1768212172000},"page":"621-631","source":"Crossref","is-referenced-by-count":0,"title":["Subsequent primary and secondary neoplasms in childhood cancer survivors"],"prefix":"10.5114","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1787-3425","authenticated-orcid":true,"given":"MONIKA","family":"BEKIESINSKA-FIGATOWSKA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5556-8021","authenticated-orcid":false,"given":"Katarzyna","family":"Bilska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5142-6616","authenticated-orcid":false,"given":"Sylwia","family":"Szkudli\u0144ska-Pawlak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1101-9319","authenticated-orcid":false,"given":"Teresa","family":"Klepacka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2612-7934","authenticated-orcid":true,"given":"Anna","family":"Raciborska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3546-9469","authenticated-orcid":false,"given":"Irena","family":"Koch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5396-225X","authenticated-orcid":false,"given":"El\u017cbieta","family":"Michalak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3061","published-online":{"date-parts":[[2025,12,27]]},"reference":[{"key":"ref-1636001","doi-asserted-by":"crossref","unstructured":"Armenian SH, Robison LL. Childhood cancer survivorship: an update on evolving paradigms for understanding pathogenesis and screening for therapy-related late effects. Curr Opin Pediatr 2013; 25: 16-22.","DOI":"10.1097\/MOP.0b013e32835b0b6a"},{"key":"ref-1636002","doi-asserted-by":"crossref","unstructured":"L\u00f6ning L, Zimmermann M, Reiter A, Kaatsch P, Henze G, Riehm H, et al. Secondary neoplasms subsequent to Berlin-Frankfurt-M\u00fcnster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. Blood 2000; 95: 2770-2775.","DOI":"10.1182\/blood.V95.9.2770.009k16_2770_2775"},{"key":"ref-1636003","doi-asserted-by":"crossref","unstructured":"Silberman AW, Quadri HS, Amersi F. Secondary malignancies: the cost of progress. Am Surg 2021; 87: 1368-1373.","DOI":"10.1177\/0003134820960081"},{"key":"ref-1636004","doi-asserted-by":"crossref","unstructured":"Friedman DL, Whitton J, Leisenring W, Mertens AC, Hammond S, Stovall M, et al. Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 2010; 102: 1083-1095.","DOI":"10.1093\/jnci\/djq238"},{"key":"ref-1636005","doi-asserted-by":"crossref","unstructured":"Becktell K, Cotchett K, Volmy R, Phelan R. Subsequent malignant neoplasms in childhood cancer survivors. Identifying risks and screening recommendations. Adv Oncol 2025; 5: 117-126.","DOI":"10.1016\/j.yao.2024.11.005"},{"key":"ref-1636006","doi-asserted-by":"crossref","unstructured":"Waespe N, Belle FN, Redmond S, Schindera C, Spycher BD, R\u00f6ssler J, et al. Cancer predisposition syndromes as a\u00a0risk factor for early second primary neoplasms after childhood cancer \u2013 a\u00a0national cohort study. Eur J Cancer 2021; 145: 71-80.","DOI":"10.1016\/j.ejca.2020.11.042"},{"key":"ref-1636007","doi-asserted-by":"crossref","unstructured":"Raciborska A, Bilska K, Kozinski T, Rodriguez-Galindo C. Subsequent malignant neoplasm of bone in children and adolescent \u2013 possibility of multimodal treatment. Curr Oncol 2022; 29: 1001-1007.","DOI":"10.3390\/curroncol29020085"},{"key":"ref-1636008","doi-asserted-by":"crossref","unstructured":"Cahan WG, Woodard HQ, Higinbotham NL, Stewart FW, Coley BL. Sarcoma arising in irradiated bone: report of 11 cases. Cancer 1948; 1: 3-29.","DOI":"10.1002\/1097-0142(194805)1:1<3::AID-CNCR2820010103>3.0.CO;2-7"},{"key":"ref-1636009","doi-asserted-by":"crossref","unstructured":"Langer T, St\u00f6hr W, Paulides M, Kremers A, D\u00f6rr HG, G\u00f6bel U, Beck JD, et al. Prospective multicenter registration of major late sequelae in sarcoma patients using the Late Effects Surveillance System (LESS). Klin Padiatr 2005; 217: 176-181.","DOI":"10.1055\/s-2005-836503"},{"key":"ref-1636010","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2016.09.094"},{"key":"ref-1636011","doi-asserted-by":"crossref","unstructured":"Yamanaka R, Hayano A. Radiation-induced schwannomas and neurofibromas: a\u00a0systematic review. World Neurosurg 2017; 104: 713-722.","DOI":"10.1016\/j.wneu.2017.05.066"},{"key":"ref-1636012","doi-asserted-by":"crossref","unstructured":"Anderson E, Linendoll N, Heilman CB, Riesenburger RI, O\u2019Leary MA, Arkun K, et al. Schwannoma formation in childhood cancer survivors exposed to total body irradiation: case series. J Adolesc Young Adult Oncol 2019; 8: 477-480.","DOI":"10.1089\/jayao.2018.0135"},{"key":"ref-1636013","doi-asserted-by":"crossref","unstructured":"Rahner N, Steinke V. Hereditary cancer syndromes. Dtsch Arztebl Int 2008; 105: 706-714.","DOI":"10.3238\/arztebl.2008.0706"},{"key":"ref-1636014","unstructured":"Aedma SK, Kasi A. Li-Fraumeni syndrome. Treasure Island (FL): StatPearls Publishing; 2023."},{"key":"ref-1636015","doi-asserted-by":"crossref","unstructured":"Racher H, Soliman S, Argiropoulos B, Chan HSL, Gallie BL, Perrier R, et al. Molecular analysis distinguishes metastatic disease from second cancers in patients with retinoblastoma. Cancer Genet 2016; 209: 359-363.","DOI":"10.1016\/j.cancergen.2016.06.001"},{"key":"ref-1636016","doi-asserted-by":"crossref","unstructured":"Chen CS, Suthers G, Carroll J, Rudzki Z, Muecke J. Sarcoma and familial retinoblastoma. Clin Exp Ophthalmol 2003; 31: 392-396.","DOI":"10.1046\/j.1442-9071.2003.00684.x"},{"key":"ref-1636017","doi-asserted-by":"crossref","unstructured":"Bekiesinska-Figatowska M. A\u00a0mini review on neurofibromatosis type 1 from the radiological point of view. J Rare Dis Res Treat 2017; 2: 45-49.","DOI":"10.29245\/2572-9411\/2017\/6.1140"},{"key":"ref-1636018","doi-asserted-by":"crossref","unstructured":"Cheng H, Shan M, Feng C, Wang X. Spinal cord ependymoma associated with neurofibromatosis 1: case report and review of the litera\u00adture. J Korean Neurosurg Soc 2014; 55: 43-47.","DOI":"10.3340\/jkns.2014.55.1.43"},{"key":"ref-1636019","doi-asserted-by":"crossref","unstructured":"Brems H, Beert E, de Ravel T, Legius E. Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. Lancet Oncol 2009; 10: 508-515.","DOI":"10.1016\/S1470-2045(09)70033-6"},{"key":"ref-1636020","doi-asserted-by":"crossref","unstructured":"Armstrong GT, Liu W, Leisenring W, Yasui Y, Hammond S, Bhatia S, et al. Occurrence of multiple subsequent neoplasms in longterm survivors of childhood cancer: a\u00a0report from the childhood cancer survivor study. J Clin Oncol 2011; 29: 3056-3064.","DOI":"10.1200\/JCO.2011.34.6585"},{"key":"ref-1636021","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14082000"},{"key":"ref-1636022","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.602482"}],"container-title":["Polish Journal of Radiology"],"original-title":[],"link":[{"URL":"https:\/\/www.polradiol.com\/pdf-213904-134193","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.polradiol.com\/pdf-213904-134193","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T10:02:59Z","timestamp":1768212179000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.polradiol.com\/Subsequent-primary-and-secondary-neoplasms-in-childhood-cancer-survivors,213904,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,27]]},"references-count":22,"alternative-id":["213904"],"URL":"https:\/\/doi.org\/10.5114\/pjr\/213904","relation":{},"ISSN":["1899-0967"],"issn-type":[{"value":"1899-0967","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,27]]}}}